Abstract

The importance of gut microbiota in human health and pathophysiology is undisputable. Despite the abundance of metagenomics data, the functional dynamics of gut microbiota in human health and disease remain elusive. Urolithin A (UroA), a major microbial metabolite derived from polyphenolics of berries and pomegranate fruits displays anti-inflammatory, anti-oxidative, and anti-ageing activities. Here, we show that UroA and its potent synthetic analogue (UAS03) significantly enhance gut barrier function and inhibit unwarranted inflammation. We demonstrate that UroA and UAS03 exert their barrier functions through activation of aryl hydrocarbon receptor (AhR)- nuclear factor erythroid 2–related factor 2 (Nrf2)-dependent pathways to upregulate epithelial tight junction proteins. Importantly, treatment with these compounds attenuated colitis in pre-clinical models by remedying barrier dysfunction in addition to anti-inflammatory activities. Cumulatively, the results highlight how microbial metabolites provide two-pronged beneficial activities at gut epithelium by enhancing barrier functions and reducing inflammation to protect from colonic diseases.

Urolithins are microbial metabolites derived from food polyphenols. Here, Singh et al. show that urolithin A and a synthetic analogue enhance gut barrier function via Nrf2-dependent pathways and mitigate inflammation and colitis in mice, highlighting a potential application for inflammatory bowel diseases.

Details

Title
Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway
Author
Singh, Rajbir 1 ; Chandrashekharappa Sandeep 2 ; Bodduluri, Sobha R 1 ; Baby, Becca V 1 ; Hegde Bindu 1 ; Kotla, Niranjan G 2 ; Hiwale, Ankita A 2 ; Saiyed Taslimarif 3 ; Patel, Paresh 3 ; Vijay-Kumar Matam 4 ; Langille, Morgan G, I 5 ; Douglas, Gavin M 5 ; Cheng, Xi 4   VIAFID ORCID Logo  ; Rouchka, Eric C 6   VIAFID ORCID Logo  ; Waigel, Sabine J 7 ; Dryden, Gerald W 7 ; Alatassi Houda 8 ; Huang-Ge, Zhang 1 ; Bodduluri, Haribabu 1 ; Vemula, Praveen K 2   VIAFID ORCID Logo  ; Jala Venkatakrishna R 1 

 University of Louisville, Department of Microbiology and Immunology, James Graham Brown Cancer Center, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 Institute for Stem Cell Biology and Regenerative Medicine (inStem), GKVK campus, Bangalore, India (GRID:grid.413008.e) (ISNI:0000 0004 1765 8271) 
 Centre for Cellular and Molecular Platforms (C-CAMP), GKVK campus, Bangalore, India (GRID:grid.413008.e) (ISNI:0000 0004 1765 8271) 
 University of Toledo College of Medicine and Life Sciences, Department of Physiology and Pharmacology, Toledo, USA (GRID:grid.267337.4) (ISNI:0000 0001 2184 944X) 
 Dalhousie University, Department of Pharmacology, Halifax, Canada (GRID:grid.55602.34) (ISNI:0000 0004 1936 8200) 
 University of Louisville, Computer Engineering and Computer Science, Kentucky Biomedical Research Infrastructure Network, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 University of Louisville, Department of Medicine, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 University of Louisville, Department of Pathology, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
Publication year
2019
Publication date
Jan 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2165652621
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.